PREMIER FINL CORP. DL-,01

Premier Inc. outlined its strategic direction at the Baird Global Healthcare Conference and expects a growth inflection in 2027, driven by investments, operational improvements and value‑enhancing acquisitions. The company has suspended share buybacks to invest in organic growth and technology, and anticipates roughly $100 million of additional free cash flow from expiring tax payments. Strong contract wins in the advisory business are expected to boost EBITDA margins; Premier aims for long‑term growth in gross management fees in pharmacy, food and medical‑surgical products. Key financials: market capitalization about $2 billion, annual revenue around $1 billion, dividend yield 3–4%, $1 billion credit line and leverage below 1; 2026 is viewed as a transition year, with a target run‑rate free cash flow of approximately $180 million. » More on de.investing.com

Premier Inc. reported earnings per share of $0.46 for the fourth fiscal quarter, beating expectations; revenue was $262.86 million, also beating consensus. The company showed slight sequential revenue growth despite a year-over-year decline, cited ongoing divestitures of its direct procurement business S2S Global and the transfer/rejection of parts of Contigo Health, and issued guidance for fiscal 2026. CEO Michael J. Alkire highlighted improved performance in the Supply Chain Services segment. » More on de.investing.com

Premier Inc. reported higher-than-expected Q4 EPS ($0.46) and revenue ($262.86 million), but the stock fell 5.81% in pre-market trading. Management cut its 2026 outlook with lower EPS guidance, while emphasizing cost reductions, innovation and the acquisition of Illumicare to support clinical decision-making. Risks remain from reimbursement uncertainties, potential Medicaid cuts and the wind-down of Contigo Health. » More on de.investing.com